Neuroone Medical Technologies Corp (NMTC) — Strategic Asset Allocation Index

Latest as of December 2022: 7.2%

Neuroone Medical Technologies Corp (NMTC) has a Strategic Asset Allocation Index of 7.2% as of December 2022. Strategic assets (PP&E of $586.92K plus long-term investments of $-) total $586.92K, measured against net assets of $8.17 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See NMTC net asset quality score to measure how much of total assets are equity-financed.

SAAI

7.2%
Strategic Assets / Net Assets

Strategic Assets

$586.92K
PP&E + LT Investments

PP&E

$586.92K
USD

Net Assets

$8.17 Million
USD

Neuroone Medical Technologies Corp Strategic Asset Allocation Index (2020–2022)

This chart shows how Neuroone Medical Technologies Corp's Strategic Asset Allocation Index has evolved across 3 annual periods from 2020 to 2022. As of December 2022, the index stands at 7.2%, representing strategic assets of $586.92K against net assets of $8.17 Million USD. For live market cap and overall valuation, see Neuroone Medical Technologies Corp (NMTC) market capitalisation.

Annual Strategic Asset Allocation Index for Neuroone Medical Technologies Corp (2020–2022)

The table below presents the year-by-year Strategic Asset Allocation Index for Neuroone Medical Technologies Corp from 2020 to 2022, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Neuroone Medical Technologies Corp book value and equity for net asset value and shareholders' equity analysis.

Year SAAI Strategic Assets (USD) PP&E LT Investments Net Assets Change (pp)
2022 5.6% $534.95K $534.95K $- $9.60 Million ▼ -2.2 pp
2021 7.8% $512.28K $512.28K $- $6.55 Million ▼ -13.9 pp
2020 21.7% $448.24K $448.24K $- $2.07 Million
pp = percentage points